$NDLS

NOODLES & Co (NDLS): Results of Operations and Financial Condition

NOODLES & Co (NDLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2ex991pressrelease.htm EX-99.1 NOODLES & COMPANY EARNINGS PRESS RELEASE DATED JULY 24, 2026 Document Exhibit 99.1 Noodles & Company Announces Second Quarter 2026 Financial Results Second Quarter 2026 Comparable Restaurant Sales Increased 10.3% System-Wide Broomfie

Original reporting
Published Jul 24, 2026, 11:55 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$NDLS
Bullish
high confidence
Mentioned
$NDLS
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NDLSBullishMed
01

Why it matters

The key tradable change is the combination of a Q2 operating improvement (margin and Adjusted EBITDA) and raised FY2026 guidance, alongside a stated expectation to reduce year-end debt to at or below 3x 2026 Adjusted EBITDA.

02

Market read

Traders can update models for NDLS using the raised FY2026 revenue, restaurant contribution margin, and Adjusted EBITDA ranges, plus the debt-paydown target.

03

What to watch

The filing highlights a strategic review and refinancing/refranchising options; execution risk and timing of any capital-structure actions could dominate the stock’s next leg.

Relevance 7/10Novelty 8/10Timing: Filed pre-market today with Q2 results and raised FY2026 guidance ranges.

Background

NDLS filed an 8-K with its Q2 2026 earnings release (Item 2.02) and provided a full-year 2026 outlook plus a continuing strategic alternatives review.

Company-level read

Ticker impact

$NDLSBullishHigh confidence
Context

Noodles & Company reported Q2 results and raised FY2026 guidance, including revenue $485M-$500M and Adjusted EBITDA $34M-$38M.

Expected impact

Likely positive near-term bias as guidance and margin/EBITDA inflect; magnitude depends on market expectations versus the raised ranges.

Evidence & confidence

The filing discloses a fresh earnings print plus explicit upward guidance ranges and liquidity/debt context, which are direct inputs to valuation and credit risk.

Market effects

Signals potential stabilization in fast-casual demand and margin recovery, which can modestly improve sentiment toward similarly positioned restaurant operators.

No specific regional read-through beyond general US restaurant demand.

Limited global relevance; primarily a US-listed restaurant turnaround story.

Counterpoint

Guidance improvement may still be fragile given ongoing restaurant closures and relatively small cash balance versus debt, so upside could be capped if sales momentum fades.

Key entities

  • NOODLES & COMPANY

    Subject of the 8-K earnings release and guidance update.

  • Board of Directors (Strategic Review)

    Initiated a strategic alternatives review that includes potential refinancing and refranchising or sale.

Related articles

$NDLSMedAI 8/10

Noodles & Company Declares it’s ‘Back’ After Historic Sales Quarter

Noodles & Company reported Q2 results showing turnaround progress. Systemwide same-store sales rose 10.3% (11.4% company-owned, 5.5% franchised) with traffic up 7.6% and average check up 3.8%. Restaurant margin rose to 17.2% and adjusted EBITDA increased 79% to $10.8M. The company raised FY outlook to $485M-$500M revenue and 8%-11% same-store growth.

$NDLSMedAI 8/10

Noodles & Company raises guidance after strong second quarter

Noodles & Company (NDLS) raised 2026 guidance after a strong Q2. Same-store sales rose 10.3% for the seventh straight quarter, with company and franchised unit growth. Revenue increased 0.5% to $127M, though it posted a $3.9M net loss. Full-year revenue is now $485M-$500M, margins 16%-17%.

$GILDHighAI 8/10

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (GILD) reported Q2 2026 with double-digit growth in commercial portfolio sales, but posted a significant loss due to $11.2B in R&D expenses from acquisitions. HIV sales rose 12% to $5.7B, while non-HIV areas like liver disease and cancer treatments also showed growth. The company raised its 2026 sales guidance and made strategic acquisitions, but faces risks from clinical development and financial obligations.

NOODLES & Co (NDLS): Results of Operations and Financial Condition — alphai